EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.
ICR Authors
Authors
de Wit, S
Manicone, M
Rossi, E
Lampignano, R
Yang, L
Zill, B
Rengel-Puertas, A
Ouhlen, M
Crespo, M
Berghuis, AMS
Andree, KC
Vidotto, R
Trapp, EK
Tzschaschel, M
Colomba, E
Fowler, G
Flohr, P
Rescigno, P
Fontes, MS
Zamarchi, R
Fehm, T
Neubauer, H
Rack, B
Alunni-Fabbroni, M
Farace, F
De Bono, J
IJzerman, MJ
Terstappen, LWMM
Manicone, M
Rossi, E
Lampignano, R
Yang, L
Zill, B
Rengel-Puertas, A
Ouhlen, M
Crespo, M
Berghuis, AMS
Andree, KC
Vidotto, R
Trapp, EK
Tzschaschel, M
Colomba, E
Fowler, G
Flohr, P
Rescigno, P
Fontes, MS
Zamarchi, R
Fehm, T
Neubauer, H
Rack, B
Alunni-Fabbroni, M
Farace, F
De Bono, J
IJzerman, MJ
Terstappen, LWMM
Document Type
Journal Article
Date
2018-11-02
Date Accepted
2018-10-25
Date Available
Abstract
The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.
Citation
Oncotarget, 2018, 9 (86), pp. 35705 - 35716
Source Title
Publisher
Impact Journals, LLC
ISSN
1949-2553
eISSN
1949-2553
Collections
Research Team
Cancer Biomarkers
Prostate Cancer Targeted Therapy Group
Prostate Cancer Targeted Therapy Group